In a 12-month period before and after erenumab use, patients with chronic migraine decreased HRU and use of acute and traditional migraine preventive medications.
Interrupting DOAC therapy before surgery can increase the risk for thrombotic events, whereas continuing these medications can increase bleeding risk. Clinicians should adopt a balanced and ...